Hemophagocytic Lymphohistiocytoses, Lymphoma
Conditions
Brief summary
The purpose of the study is to describe Hemophagocytic lymphohistiocytosis (HLH) in patients with lymphoma to identify possible therapeutic strategies to improve overall survival of the patients with lymphoma associated hemophagocytic lymphohistiocytosis.
Detailed description
Retrospective, multi-institutional study focused on describing the clinical features, laboratory parameters, treatments, and outcomes among individuals presenting with HLH in the setting of a lymphoma
Interventions
None listed
Sponsors
University of Alabama at Birmingham
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
* Patients with lymphoma that are fulfilling at least one of the following: A. Meeting 5 of 8 HLH-2004 diagnostic criteria OR B. Are OHI index positive (sCD25\>3,900 U/mL and ferritin\>1,000 ng/mL)
Exclusion criteria
* Patients developing HLH\> 1 month after lymphoma diagnosis (for aggressive lymphomas) * Patients with incomplete treatment and response documentation
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| To determine the factors predicting 180 days overall survival of patients with cancer that are HLH-2004/OHI+ | The participant's survival would be assessed at 180 days from the malignancy diagnosis | The investigators will gather data on different treatments received, time to treatment, and other factors and determine which is associated with survival. |
Countries
United States
Contacts
CONTACTGaurav Goyal, MD
PRINCIPAL_INVESTIGATORGaurav Goyal, MD
University of Alabama at Birmingham
Outcome results
None listed